Navigation Links
Hyperthermia With Chemotherapy Improves Sarcoma Healing

Co-operation between GSF and clinic improves outlook for sarcoma patients: Effectiveness of local, deep hyperthermia proved in phase III study .

Hyperthermia, combined with chemotherapy, improves the chances of healing and survival of patients with low-lying, soft tissue sarcomas.

At the Annual General Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, which ended last week, the GSF scientist, Prof. Dr Rolf D. Issels, presented the results of the first, randomised, worldwide phase III study in which the effectiveness and superiority of the combined-therapy methods are proven, in comparison with results from chemotherapy alone.

The study of 341 high-risk patients with deep, local sarcomas shows a significant improvement in the response of the tumour and in the survival of those patients who were treated by means of a combination of chemotherapy and of local, deep hyperthermia, in addition to operative removal of the sarcoma. This combined therapy has been applied already to a large number of patients in advance of surgery.

The well respected study results from the Clinical Co-operation Group Hyperthermia, which has existed since 1999 between the GSF National Research Centre for Environment and Health in Munich-Neuherberg and the Grohadern Medical Centre of the University of Munich.

Their spectrum of research extends from clinical analysis of deep hyperthermia for cancer therapy up to biological research in the areas of immunobiology and cell biology.

The head of the Clinical Co-operation Group Hyperthermia, Prof. Dr Rolf Issels, has been working at GSF, since the mid-80s, on the use of local, deep hyperthermia as a cancer therapy.

From the beginning, tumours of soft tissues and bones, which start from the connective tissue and are called sarcomas, were taken as examples.

The scientists were especially interested together with related bi ological research - in the question whether certain sarcomas could be better treated with a combination of hyperthermia and other forms of therapy.

In the course of local, deep hyperthermia, tumours are warmed to 40-44 Celsius, with, the aid of electromagnetic waves. At temperatures of 42 C, cells begin to die, on account of the heat. The combination therapy developed at GSF and the Grohadern Medical Centre exploits the fact that tumour cells are more vulnerable at 40 C to the immune system and also to radiotherapy and chemotherapy.

In the past years, the results gained in the treatment of sarcomas have encouraged the research group to apply their knowledge to other forms of tumour.

At the present time, within the framework of a part body hyperthermia project plan, they are investigating whether the combination of chemotherapy and radiotherapy with hyperthermia leads to better treatment results in cases of colon and rectum cancers and of pancreatic carcinoma, as well.

Under the guidance of GSF, a Virtual Institute of Excellence has been founded between the Clinical Co-operation Group Hyperthermia at the Grohadern Medical Centre and the Medical Clinic Charite Berlin, in order to promote the project plan, which will initially be sponsored for three years by the Initiative and Networking Fund of the Helmholtz Association of German Research Centres.

The Scientific Technical Director of GSF, Prof. Dr Wess, regards this as a successful example of translational research. The concept of research in co-operation groups together with clinical partners and the creation of clinical research platforms is an essential prerequisite for the prompt application of knowledge from fundamental research to clinical practice and vice versa.

Contact the GSF Press Office: GSF - Forschungszentrum fr Umwelt und Gesundheit Abteilung Kommunikation Tel: 089/3187-2460 Fax 089/3187-3324 E-mail: oea@gsf. de


'"/>




Related medicine news :

1. Research Reveals Way to Speed Up Treatment of Deadly Malignant Hyperthermia
2. Acupuncture May Help Chemotherapy Side Effects
3. Chemotherapy Pill Has Fewer Side Effects Than IV
4. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
5. Therapy Boosts Chemotherapy Effects
6. Chemotherapy Effective for Bladder Cancer
7. New Method Of Delivering Chemotherapy
8. The Benefits Of Chemotherapy For Women With Ovarian Cancer
9. New Compound Could Strengthen The Effect Of Chemotherapy
10. Older Breast Cancer Patients Can Be Effectively Treated With Chemotherapy
11. Treating Testicular Cancer With A Single Dose Of Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... AMSTERDAM , December 8, 2016 Information ... TM metrics in Scopus , the world,s largest ... free access to comprehensive metrics for journals from over 5,000 publishers. ... publish, which journals to subscribe to and when to adjust a ... , , ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
(Date:12/8/2016)... 2016 According to a new market research report ... Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart watch, Patch), ... global market, in terms of value, is projected to reach 12.14 Billion ... 18.0% during the forecast period. Continue Reading ... ...
Breaking Medicine Technology: